Medical Crossfire®: Personalized Regimens for Managing Hemophilia A: Selecting an Optimal Recombinant FVIII Agent

Target Audience
This online educational activity is directed toward hematologists, primary care clinicians, nurse practitioners, physician assistants, nurses, and other health care professionals who are involved in the management of hemophilia.

Activity Overview
Over the past 20 years, substantial advances in the treatment of hemophilia A have allowed patients to take greater control of their disease. The primary goals of hemophilia A treatment are to prevent bleeding episodes, reduce long-term complications of bleeding, and arrest bleeding if it occurs. Health care providers should understand the underlying etiology and pathophysiology of hemophilia A. In addition, providers should be familiar with how patients perceive their disease and how health-related and economic burdens of hemophilia A impact patients and their families.

Learning Objectives
Upon completion of this activity, you should be better able to:

Explain the role of FVIII therapy in managing bleeding in patients with hemophilia A
Evaluate clinical trial data for new and emerging recombinant FVIII products for the prophylactic treatment of patients with hemophilia A
Discuss the role of pharmacokinetic-tailored prophylaxis in selecting a recombinant FVIII product for the management of hemophilia A
Develop personalized prophylactic treatment plans for patients with hemophilia A